Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Starbucks Corp SBUX

Alternate Symbol(s):  N.SBUX

Starbucks Corporations is a coffee company, which roasts, markets and retails specialty coffee in the world. The Company operates in 86 markets and has approximately 38,000 stores worldwide. It has three segments: North America, International and Channel Development. North America segment includes the United States and Canada. International segment includes China, Japan, Asia Pacific, Europe, Middle East and Africa, Latin America and Caribbean. North America and International segments include both the Company-operated and licensed stores. Channel Development segment includes roasted whole bean and ground coffees, Starbucks- and Teavana-branded single-serve products, a variety of ready-to-drink beverages, such as Frappuccino and Starbucks Doubleshot, foodservice products and other branded products sold worldwide outside the Company-operated and licensed stores. A large portion of its Channel Development business operates under a licensed model of the Global Coffee Alliance with Nestle.


NDAQ:SBUX - Post by User

Post by RomaJoyon Feb 05, 2022 2:09am
206 Views
Post# 34400479

FSD Pharma Inc: Lucid MS Video

FSD Pharma Inc: Lucid MS VideoFSD Pharma is pleased to share pre-clinical data demonstrating the effectiveness of its lead drug candidate, Lucid-MS, in treating Multiple Sclerosis. The unique potential therapeutic value of Lucid-MS is an industry-first and we want to share the visual evidence of functional recovery of pre-clinical subjects in this video!
<< Previous
Bullboard Posts
Next >>